Related Experiment Video
Updated: Jun 10, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Emerging clinical applications in cardiovascular pharmacogenomics
1Division of Cardiovascular Diseases, Scripps Clinic, Scripps Translational Science Institute, La Jolla, CA, USA.
Wiley Interdisciplinary Reviews. Systems Biology and Medicine
|August 24, 2010
Summary
Genomic biomarker information can predict drug response, but clinical implementation is lacking. Advances in genome-wide association studies and decreasing sequencing costs are paving the way for personalized medicine, especially in cardiovascular disease.
Area of Science:
- Pharmacogenomics
- Genomic Medicine
- Cardiovascular Disease Research
Background:
- Over 25% of US outpatient prescriptions have available human genomic biomarker data for drug safety and efficacy.
- Clinical practice has not systematically implemented genomic data due to modest predictive capacity and translation challenges.
- Emerging genome-wide association studies (GWAS) are identifying key variants impacting drug absorption, metabolism, and excretion.
Purpose of the Study:
- To review clinically compelling pharmacogenomic examples in cardiovascular disease.
- To illustrate the potential of genomic medicine in future cardiovascular disease treatment.
- To highlight the need for clinical preparedness in utilizing genomic data.
Main Methods:
- Review of current literature on pharmacogenomics in cardiovascular disease.
- Analysis of emerging genome-wide association studies (GWAS) and their validation.
- Discussion of the impact of decreasing DNA sequencing costs on genomic data accessibility.
Main Results:
- Identification of key genetic variants strongly predicting drug response is accelerating.
- Validation of these variants in large independent cohorts is increasing confidence.
- Pharmacogenomic applications are showing significant promise in cardiovascular medicine.
Conclusions:
- Genomic data holds immense potential for personalized drug selection and improved patient outcomes.
- The clinical community must prepare for the integration of pharmacogenomics into routine practice.
- Genomic medicine is poised to revolutionize cardiovascular disease treatment.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...